NCT01621633

A Study of LCZ696 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers

A Single-dose, Open-label Parallel-group Study to Assess the Pharmacokinetics of LCZ696 in Subjects With Hepatic Impairment Compared to Matched Healthy Subjects

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

This is a study to characterize the pharmacokinetics as well as safety and tolerability of a single oral dose of LCZ696 200 mg in subjects with mild and moderate hepatic impairment compared to matched healthy subjects

Conditions

• Hepatic Impairment

Interventions

Type	Name	Description
DRUG	LCZ696

Timeline

• Start date: 2012-09-01
• Primary completion: 2013-01-01
• Completion: 2013-01-01
• First posted: 2012-06-18
• Last updated: 2015-08-10
• Results posted: 2015-08-10

Locations

1 site across 1 country: Germany